Biotech Breakout: This Microcap Locks In Up to $400 Million to Fuel Late-Stage Push

2026-02-13 10:04:10 ET

In biotechnology, few milestones carry more weight than securing the capital required to cross the finish line. As clinical-stage companies approach pivotal trials and potential commercialization, access to substantial funding can dramatically reshape both timelines and investor perception.

Shares of Immunic, Inc. ( Nasdaq: IMUX ) are climbing Friday morning after the late-stage biotechnology company announced an oversubscribed private placement of up to $400 million, priced at the market under Nasdaq rules. The financing includes $200 million in upfront gross proceeds, with the potential for an additional $200 million upon exercise of accompanying warrants.

The company stated that the proceeds are expected to accelerate its transition from a research-driven organization into a fully integrated commercial-stage company. Immunic plans to use the capital to complete its ongoing Phase 3 ENSURE clinical trials of vidofludimus calcium in relapsing multiple sclerosis, with top-line data anticipated by the end of 2026. Management indicated that, pending positive results, a New Drug Application submission in the United States is targeted for mid-2027, with potential regulatory approval in 2028.

In parallel, Immunic is preparing to initiate a Phase 3 clinical program in primary progressive multiple sclerosis later this year, a study expected to run approximately three and a half to four years. With both pivotal programs advancing, the company is positioning vidofludimus calcium as a next-generation oral therapy designed to address both inflammatory relapses and neurodegenerative progression in multiple sclerosis.

Vidofludimus calcium is described as a first-in-class therapy combining activation of the nuclear receptor-related 1 pathway, aimed at promoting neuroprotection, with selective inhibition of dihydroorotate dehydrogenase to reduce inflammatory damage. Management believes this dual mechanism could address both relapse-associated worsening and progression independent of relapse activity, two central drivers of disability in MS.

The financing was led by existing investor BVF Partners L.P., with participation from several institutional investors including Aberdeen Investments, OrbiMed, RA Capital Management, Janus Henderson Investors, and Vivo Capital, among others. The company also entered into a separate agreement to cancel certain previously issued warrants in exchange for a future royalty interest tied to net sales of vidofludimus calcium, further streamlining its capital structure.

Alongside the financing, Immunic announced leadership changes as it prepares for commercialization. Co-Founder and CEO Dr. Daniel Vitt will begin a search for a new chief executive with commercial expertise in the MS space, while transitioning to a senior role focused on scientific strategy. Simona Skerjanec, formerly Global Head of Neuroscience and Rare Diseases at Roche, has been elevated to interim Chairperson of the Board, and Thor Nagel of BVF Partners has joined the board as well.

The company expects that, combined with existing cash and marketable securities, the proceeds will fund operations into late 2027.

Shares of IMUX are up 26.4% to $1.10 in early Friday morning trading.

Copyright © 2026 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

View more of this article on AllPennyStocks.com.

About AllPennyStocks.com Media, Inc.:

Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.

Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.

AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.

Contact:

AllPennyStocks.com Media, Inc.

Email: ads@allpennystocks.com

Phone: (800) 558-4560 Ext: 101